These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 16395746

  • 1. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy.
    Comby E, Tanaff P, Mariotte D, Costentin-Pignol V, Marcelli C, Ballet JJ.
    J Rheumatol; 2006 Jan; 33(1):24-30. PubMed ID: 16395746
    [Abstract] [Full Text] [Related]

  • 2. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.
    De Rycke L, Kruithof E, Van Damme N, Hoffman IE, Van den Bossche N, Van den Bosch F, Veys EM, De Keyser F.
    Arthritis Rheum; 2003 Apr; 48(4):1015-23. PubMed ID: 12687543
    [Abstract] [Full Text] [Related]

  • 3. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.
    Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN.
    Arthritis Rheum; 2000 Nov; 43(11):2383-90. PubMed ID: 11083258
    [Abstract] [Full Text] [Related]

  • 4. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
    De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F.
    Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
    [Abstract] [Full Text] [Related]

  • 5. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
    Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T.
    Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
    [Abstract] [Full Text] [Related]

  • 6. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha.
    Eriksson C, Engstrand S, Sundqvist KG, Rantapää-Dahlqvist S.
    Ann Rheum Dis; 2005 Mar; 64(3):403-7. PubMed ID: 15297281
    [Abstract] [Full Text] [Related]

  • 7. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response.
    Haraoui B, Cameron L, Ouellet M, White B.
    J Rheumatol; 2006 Jan; 33(1):31-6. PubMed ID: 16395747
    [Abstract] [Full Text] [Related]

  • 8. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
    Lequerré T, Jouen F, Brazier M, Clayssens S, Klemmer N, Ménard JF, Mejjad O, Daragon A, Tron F, Le Loët X, Vittecoq O.
    Rheumatology (Oxford); 2007 Mar; 46(3):446-53. PubMed ID: 16899502
    [Abstract] [Full Text] [Related]

  • 9. The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study.
    Flendrie M, Creemers MC, Welsing PM, van Riel PL.
    Rheumatology (Oxford); 2005 Apr; 44(4):472-8. PubMed ID: 15598707
    [Abstract] [Full Text] [Related]

  • 10. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement.
    Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, Tincani A, Valesini G.
    Ann Rheum Dis; 2004 Oct; 63(10):1218-21. PubMed ID: 15361374
    [Abstract] [Full Text] [Related]

  • 11. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.
    Elkayam O, Bashkin A, Mandelboim M, Litinsky I, Comaheshter D, Levartovsky D, Mendelson E, Wigler I, Caspi D, Paran D.
    Semin Arthritis Rheum; 2010 Jun; 39(6):442-7. PubMed ID: 19246078
    [Abstract] [Full Text] [Related]

  • 12. Autoantibodies in early seropositive rheumatoid arthritis, before and during disease modifying antirheumatic drug treatment.
    Paulus HE, Wiesner J, Bulpitt KJ, Patnaik M, Law J, Park GS, Wong WK.
    J Rheumatol; 2002 Dec; 29(12):2513-20. PubMed ID: 12465144
    [Abstract] [Full Text] [Related]

  • 13. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis.
    Braun-Moscovici Y, Markovits D, Zinder O, Schapira D, Rozin A, Ehrenburg M, Dain L, Hoffer E, Nahir AM, Balbir-Gurman A.
    J Rheumatol; 2006 Mar; 33(3):497-500. PubMed ID: 16511906
    [Abstract] [Full Text] [Related]

  • 14. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register.
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [Abstract] [Full Text] [Related]

  • 15. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.
    Shergy WJ, Isern RA, Cooley DA, Harshbarger JL, Huffstutter JE, Hughes GM, Spencer-Smith EA, Goldman AL, Roth SH, Toder JS, Warner D, Quinn A, Keenan GF, Schaible TF, PROMPT Study Group. Profiling Remicade Onset with MTX in a Prospective Trial.
    J Rheumatol; 2002 Apr; 29(4):667-77. PubMed ID: 11950005
    [Abstract] [Full Text] [Related]

  • 16. Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab.
    Elkayam O, Burke M, Vardinon N, Zakut V, Yitzhak RB, Paran D, Levartovsky D, Litinsky I, Caspi D.
    Autoimmunity; 2005 Mar; 38(2):155-60. PubMed ID: 16040336
    [Abstract] [Full Text] [Related]

  • 17. Fatigue, rheumatoid arthritis, and anti-tumor necrosis factor therapy: an investigation in 24,831 patients.
    Wolfe F, Michaud K.
    J Rheumatol; 2004 Nov; 31(11):2115-20. PubMed ID: 15517621
    [Abstract] [Full Text] [Related]

  • 18. Predictors of infusion reactions during infliximab treatment in patients with arthritis.
    Kapetanovic MC, Larsson L, Truedsson L, Sturfelt G, Saxne T, Geborek P.
    Arthritis Res Ther; 2006 Nov; 8(4):R131. PubMed ID: 16869978
    [Abstract] [Full Text] [Related]

  • 19. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
    Poulalhon N, Begon E, Lebbé C, Lioté F, Lahfa M, Bengoufa D, Morel P, Dubertret L, Bachelez H.
    Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874
    [Abstract] [Full Text] [Related]

  • 20. Early and late effect of infliximab on circulating dendritic cells phenotype in rheumatoid arthritis patients.
    Balanescu A, Radu E, Nat R, Regalia T, Bojinca V, Ionescu R, Balanescu S, Savu C, Predeteanu D.
    Int J Clin Pharmacol Res; 2005 Feb; 25(1):9-18. PubMed ID: 15864873
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.